AIMOVIG

(Erenumab-Aooe)

Phase 2

Amgen

AIMOVIG is one of 3 biologic programs targeting Schwannomatosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

SchwannomatosisRecruiting

SchwannomatosisPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Schwannomatosis

#DrugCompanyPhaseTrials

Aimovig

Amgen

Phase 2

1 2

Sylvant

RRECORDATI GROUP

Phase 2

1 3

AIMOVIG

Amgen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Schwannomatosis

NCT05684692

Clinical

Trials by Indication[1]

Schwannomatosis1 trial

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05684692·40 enrolled

Regulatory

FDA Approval Timeline[4]

May 17, 2018

AIMOVIG

BLA BLA761077

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Erenumab-Aooe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Erenumab-Aooe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Erenumab-Aooe. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761077). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Amgen

AIMOVIG

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Schwannomatosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News